Skip to main content

Advertisement

SpringerLink
Log in

The use of anakinra in juvenile arthritis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Interleukin-1 (IL-1), one of the major pro-inflammatory cytokines, plays an important role in the pathophysiology and progression of adult and pediatric arthritis. Inhibiting IL-1 activity by using a recombinant human IL-1 receptor antago-nist (anakinra) given alone or in combination with metho-trexate, moderately reduced the signs and symptoms of active arthritis in adults and slowed the rate of radiographic destruction. Preliminary results from an open label portion of a trial in children with polyarticular arthritis show similar out-comes with 58% of children exhibiting clinical improvements based on the Juvenile Arthritis 30% Core Set Criteria. The drug has an overall favorable safety profile and injection-site reactions are the most commonly reported adverse event in both groups. However despite its rather disappointing effect in polyarticular arthritis, anakinra is being discovered as an effective treatment of systemic arthritis and children with mutations in the NALP3/CIAS1/PYPAF1 genes leading to autoimmune inflammatory disorders such as neonatal-onset multisystem inflammatory disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Firestein GS, Alvaro-Gracia JM, Maki R: Quantitative analysis of gene expression in rheumatoid arthritis. J Immunol 1990, 144:3347–3353.

    PubMed  CAS  Google Scholar 

  2. Fontana A, Hengartner H, Weber E, et al.: Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int 1982, 2:49–53.

    Article  PubMed  CAS  Google Scholar 

  3. Quale JA, Adams S, Bucknall RC, et al.: Interleukin 1 expres-sion by neutrophils in rheumatoid arthritis. Ann Rheum Dis 1995, 545:930–933.

    Google Scholar 

  4. Tawara T, Shingu M, Nobunaga M, Naono T: Effects of recom-binant human IL-1 beta on production of prostaglandin E2, leukotriene B4, NAG, and superoxide by human synovial cells and chondrocytes. Inflammation 1991, 15:145–157.

    Article  PubMed  CAS  Google Scholar 

  5. Dinarello CA, Cannon JG, Mier JW, et al.: Multiple biological activities of human recombinant interleukin 1. J Clin Invest 1986, 77:1734–1739.

    PubMed  CAS  Google Scholar 

  6. Dumonde DC, Wolstencroft RA, Panayi GS, et al.: "Lymphok-ines": nonantibody mediators of cellular immunity gener-ated by lymphocyte activation. Nature 1969, 224:38–42.

    Article  PubMed  CAS  Google Scholar 

  7. Waksman BH, Cohen S, Pick E, Oppenheim JJ: Biology of the Lymphokines. New York: Academic Press Inc; 1979.

    Google Scholar 

  8. Dinarello CA, Ikejima T, Warner SJ, et al.: Interleukin 1 induces interleukin 1. I: induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 1987, 139:1902–1910.

    PubMed  CAS  Google Scholar 

  9. Dinarello CA, Cannon JG, Wolff SM, et al.: Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986, 163:1433–1450.

    Article  PubMed  CAS  Google Scholar 

  10. Phillip R, Epstein LB: Tumour necrosis factor as immuno-modulator and mediator of monocyte cytotoxicity induced by itself, gamma interferon and interleukin-1. Nature 1986, 323:86–89.

    Article  Google Scholar 

  11. Dinarello CA, Moldawer LL: Proinflammatory and Anti-inflamma-tory cytokines in rheumatoid arthritis; a primer for clinicians, second edition. Thousand Oaks: Amgen Inc.; 2000. Excellent resource of info for clinicians interested in cytokine immunology.

    Google Scholar 

  12. Colotta F, Re F, Muzio M, et al.: Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993, 261:472–475.

    Article  PubMed  CAS  Google Scholar 

  13. Colotta F, Dower SK, Sims JE, et al.: The types II "decoy" receptor: a novel regulatory pathway for interleukin-1. Immunol Today 1994, 15:562–566.

    Article  PubMed  CAS  Google Scholar 

  14. Re F, Muzio M, De RossiM, et al.: The type II "receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med 1994, 179:739–743.

    Article  PubMed  CAS  Google Scholar 

  15. Auron PE: The interleukin 1 receptor: ligand interactions and signal transduction. Cytokine Growth Factor Rev 1998, 9:221–237.

    Article  PubMed  CAS  Google Scholar 

  16. Cullinan EB, Kwee L, Nunes P, et al.: IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol 1998, 161:5614–5620.

    PubMed  CAS  Google Scholar 

  17. Sims J, Gayle M, Slack J, et al.: Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci U S A 1993, 90:6155–6159.

    Article  PubMed  CAS  Google Scholar 

  18. Arend WP, Malyak M, Smith MF, et al.: Binding of IL-1_, IL-1_, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. Immunol 1994, 153:4766–4774.

    CAS  Google Scholar 

  19. Giri JG, Wells J, Dower SK, et al.: Elevated levels of shed type II IL-1receptor in sepsis: potential role for type II receptor regulation of IL-1 responses. J Immunol 1994, 153:5802–5809.

    PubMed  CAS  Google Scholar 

  20. Gershenwald JE, Fong YM, Fahey TJ, et al.: Interleukin-1 recep-tor blockade attenuates the host inflammatory response. Proc Natl Acad Sci U S A 1990, 87:4966–4970.

    Article  PubMed  CAS  Google Scholar 

  21. Eisenberg SP, Evans RJ, Arend WP, et al.: Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990, 343:341–346.

    Article  PubMed  CAS  Google Scholar 

  22. Carter DB, Deibel MRJ, Dunn CJ, et al.: Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990, 344:633–638.

    Article  PubMed  CAS  Google Scholar 

  23. Dripps DJ, Brandhuber BJ, Thompson RC, et al.: Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991, 266:10331–10336.

    PubMed  CAS  Google Scholar 

  24. Arend WP, Malyak M, Guthridge CJ, et al.: Interleukin-1 receptor antagonist: role in biology. Ann Rev Immunol 1998, 16:27–55. Excellent review on IL-1 biology.

    Article  CAS  Google Scholar 

  25. Granowitz EV, Porat R, Mier JW, et al.: Pharmacokinetics, safety, and immunomodulatory effects of human recombi-nant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992, 4:353–360; 1999, 276:R644–R651.

    Article  PubMed  CAS  Google Scholar 

  26. Dower SK, Fanslow W, Jacobs C, et al.: Interleukin-1 antago-nists. Therapeutic Immunol 1994, 1:113–122.

    CAS  Google Scholar 

  27. Butler DM, Maini RN, Feldmann M, et al.: Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995, 6:225–230.

    PubMed  CAS  Google Scholar 

  28. Feige U, Karbowski A, Rordorf-Adam C, et al.: Arthritis induced by continuous infusion of hr-interleukin-1 into the rabbit knee-joint. Int J Tiss Reac 1989, 11:225–238.

    CAS  Google Scholar 

  29. Geiger T, Towbin H, Cosenti-Vargas A, et al.: Neutralization of interleukin-1b activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute phase response. Clin Exp Rheumatol 1993, 11:515–522.

    PubMed  CAS  Google Scholar 

  30. van den BergWB, Joosten LAB, Helsen M, et al.: Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994, 95:237–243.

    Article  PubMed  Google Scholar 

  31. Horai R, Saijo S, Tanioka H, et al.: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in IL-1 receptor antagonist-deficient mice. J Exp Med 2000, 191:313–320.

    Article  PubMed  CAS  Google Scholar 

  32. Bargetzi MJ, Lantz M, Smith CG, et al.: Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necro-sis factor binding proteins. Cancer Res 1993, 53:4010–4013.

    PubMed  CAS  Google Scholar 

  33. Krane SM, Conca W, Stephenson ML, et al.: Mechanisms of matrix degradation in rheumatoid arthritis. Ann N Y Acad Sci 1990, 580:340–354.

    Article  PubMed  CAS  Google Scholar 

  34. Dayer JM, de Rochemonteix B, Burrus B, et al.: Human recom-binant interleukin 1stimulates collagenase and prostaglan-din E2 production by human synovial cells. J Clin Invest 1986, 77:645–648.

    PubMed  CAS  Google Scholar 

  35. Eastgate JA, Symons JA, Wood NC, et al.: Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988, 2:706–709.

    Article  PubMed  CAS  Google Scholar 

  36. Grom AA, Murray KJ, Luyrink L, et al.: Patterns of expression of tumor necrosis factor a, tumor necrosis factor b, and their receptors in synovia of patients with juvenile rheuma-toid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996, 39:1703–1710.

    Article  PubMed  CAS  Google Scholar 

  37. Guerne PA: Cytokines in juvenile arthritis. Rev Rhum Engl Ed 1996, 63:153–158.

    PubMed  CAS  Google Scholar 

  38. Kutukculer N, Caglayan S, Aydogdu F: Study of pro-inflamma-tory (TNF-a, IL-1a, IL-6) and T-cell-derived (IL-2, IL-4) cyto-kines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin Rheumatol 1998, 17:288–292.

    Article  PubMed  CAS  Google Scholar 

  39. Murray KJ, Grom AA, Thompson SD, et al.: Contrasting cyto-kine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol 1998, 25:1388–1398.

    PubMed  CAS  Google Scholar 

  40. Tetta C, Camussi G, Modena V, et al.: Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990, 49:665–667.

    PubMed  CAS  Google Scholar 

  41. van LeeuwenMA, Westra J, Limburg PC, et al.: Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. Ann Rheum Dis 1995, 54:33–38.

    Article  PubMed  Google Scholar 

  42. Date Y, Seki N, Kamizono S, et al.: Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5’-flanking region of the TNFa gene and HLA genes. Arthritis Rheum 1999, 42:2577–2582.

    Article  PubMed  CAS  Google Scholar 

  43. de BenedettiF, Massa M, Robbioni P, et al.: Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991, 34:1158–1163.

    Article  PubMed  Google Scholar 

  44. de BenedettiF, Martini A: Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998, 25:203–207. Important study to understand the cytokine profile in systemic JA.

    PubMed  Google Scholar 

  45. Pignatti P, Vivarelli M, Meazza C, et al.: Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J Rheumatol 2001, 28:1670–1676.

    PubMed  CAS  Google Scholar 

  46. Maeno N, Takei S, Nomura Y, et al.: Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthri-tis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al [letter]. Arthritis Rheum 2002, 46:2539–2541.

    Article  PubMed  Google Scholar 

  47. Muller K, Zak M, Nielsen S, et al.: Interleukin-1 receptor antagonist in neonates, children and adults, and in patients with pauci- and polyarticular onset juvenile chronic arthritis. Clin Exp Rheum 1997, 15:439–444.

    CAS  Google Scholar 

  48. Ou LS, See LC, Wu CJ, et al.: Association between serum inflammatory cytokines and disease activity in juvenile idiopathic arthritis. Clin Rheumatol 2002, 21:52–56.

    Article  PubMed  CAS  Google Scholar 

  49. Lebsack ME, Paul CC, Bloedow DC, et al.: Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1991, 34(Suppl):S67.

    Google Scholar 

  50. Campion GV, Lebsack ME, Lookabaugh J, et al.: Dose rage and dose frequency study of recombinant interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1 Ra arthritis study group. Arthritis Rheum 1996, 39:1092–1101.

    Article  PubMed  CAS  Google Scholar 

  51. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41:2196–2204. Pivotal study of IL1-Ra in rheumatoid arthritis.

    Article  PubMed  CAS  Google Scholar 

  52. Cohen SB, Moreland LW, Cush JJ, et al.: A multicenter, double blind, randomized, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with back-ground methotrexate. Ann Rheum Dis 2004, 63:1062–1068.

    Article  PubMed  CAS  Google Scholar 

  53. Cohen S, Hurd E, Cush J, et al.: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:614–624.

    Article  PubMed  CAS  Google Scholar 

  54. Reiff A, Porras O, Rudge S, et al.: Preliminary data from a study of Kineret TM (anakinra) in children with juvenile rheuma-toid arthritis. Arthritis Rheum 2002, 46(Suppl):S496. First and only published experience of random controlled trial with IL-1Ra in JA.

    Google Scholar 

  55. Calabro JJ, Holgersson WB, Sonpal GM, et al.: Juvenile rheuma-toid arthritis: a general survey of 100 patients observed for 15 years. Sem Arthritis Rheum 1976, 5:257–298.

    Article  CAS  Google Scholar 

  56. Lomater C, Gerloni V, Gattinara M, et al.: Systemic onset juvenile rheumatoid arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000, 27:491–496. Important outcome study in systemic JA.

    PubMed  CAS  Google Scholar 

  57. Spiegel LR, Schneider R, Lang BA, et al.: Early predictors of poor functional outcome in systemic-onset juvenile rheuma-toid arthritis: a multicenter cohort study. Arthritis Rheum 2000, 43:2402–2409.

    Article  PubMed  CAS  Google Scholar 

  58. Sandborg C, Holmes T, Lee T, et al.: Analysis of candidate predictors for progression to severe joint damage in systemic onset JRA. J Rheum 2005, Submitted.

  59. Wallace CA, Levinson JE: Juvenile rheumatoid arthritis: outcome and treatment for the 1990’s. Rheum Dis Clin North Am 1991, 17:891–905.

    PubMed  CAS  Google Scholar 

  60. Ansell BM, Wood PN: Prognosis in juvenile chronic polyarthritis. Clin Rheumatic Dis 1976, 2:397–412.

    Google Scholar 

  61. Hafner R, Truckenbrodt H: Course and prognosis of systemic juvenile chronic arthritis-retrospective study of 187 patients. Klin Padiatr 1986, 198:401–407.

    Article  PubMed  CAS  Google Scholar 

  62. Wulffraat NM, Brinkman D, Ferster A, et al.: Long-term follow-up of autologous stem cell transplantation for refractory juvenile idiopathic arthritis. Bone Marrow Transplant 2003, 32(Suppl 1):S61-S64.

    Article  PubMed  CAS  Google Scholar 

  63. Mangge H, Schauenstein K: Cytokines in juvenile rheumatoid arthritis (JRA). Cytokine 1998, 10:471–480.

    Article  PubMed  CAS  Google Scholar 

  64. De Benedetti F, Pignatti P, Massa M, et al.: Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1995, 13:779–784.

    Google Scholar 

  65. Lepore L, Pennesi M, Saletta S, et al.: Study of IL-2, IL-6, TNF-alpha, IF-gamma and delta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin Exp Rheumatol 1994, 12:561–565.

    PubMed  CAS  Google Scholar 

  66. De Benedetti F, Massa M, Robbioni P, et al.: Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991, 34:1158–1163.

    Article  Google Scholar 

  67. Madson KL, Moore TL, Lawrence JM, et al.: Cytokine levels in serum and synovial fluid of patients with juvenile rheuma-toid arthritis. J Rheumatol 1994, 21:2359–2369.

    PubMed  CAS  Google Scholar 

  68. Kawashima M, Yamamura M, Taniai M, et al.: Levels of inter-leukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still’s disease. Arthritis Rheum 2001, 44:550–560.

    Article  PubMed  CAS  Google Scholar 

  69. Kawaguchi Y, Terajima H, Harigai M, et al.: Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still’s disease. Arthritis Rheum 2001, 44:1716–1717.

    Article  PubMed  CAS  Google Scholar 

  70. Maeno N, Takei S, Nomura Y, et al.: Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. Arthritis Rheum 2002, 46:2539–2541.

    Article  PubMed  Google Scholar 

  71. De BenedettiF, Massa M, Pignatti P, et al.: Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994, 93:2114–2119.

    PubMed  Google Scholar 

  72. Keul R, Heinrich PC, Muller-Newen G, et al.: A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 1998, 10:729–734.

    Article  PubMed  CAS  Google Scholar 

  73. deBenedetti F, Massa M, Robbioni P, et al.: Correlation of serum IL-6 levels with joint involvement and thrombocytosis in systemic juvenile chronic arthritis. Arthritis Rheum 1991, 34:1158–1163.

    Article  PubMed  Google Scholar 

  74. Pignatti P, Vivarelli M, Meazza C, et al.: Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J Rheumatol 2001, 28:1670–1676.

    PubMed  CAS  Google Scholar 

  75. Fishman D, Gaulds G, Jeffery R, et al.: The effect of polymor-phisms in the Interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102:1369–1376.

    PubMed  CAS  Google Scholar 

  76. deBenedetti F, Martini A: Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998, 25:203–207.

    PubMed  Google Scholar 

  77. Yilmaz M, Kendirli SG, Altinatas D, et al.: Cytokine levels in serum of patient with juvenile rheumatoid arthritis. Clin Rheumatol 2001, 20:30–35.

    Article  PubMed  CAS  Google Scholar 

  78. Kimura Y, Pinho P, Walco G, et al.: Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005, 32:935–942. Important study investigating the effect of TNF blockade in systemic JA.

    PubMed  CAS  Google Scholar 

  79. Iwamoto M, Nara H, Hirata D, et al.: Dramatic improvement of intractable adult-onset Still’s disease by intravenous humanized anti-interleukin 6 receptor antibody (MRA). Arthritis Rheum 2001, 44(Suppl):S118.

    Google Scholar 

  80. Yokota S, Miyamae T, Imagawa T, et al.: Long-term therapeutic efficacy of humanized anti-IL-6-receptor antibody for systemic juvenile idiopathic arthritis. Arthritis Rheum 2002, 46(Suppl):S479.

    Google Scholar 

  81. Yokata S, Miyamae T, Imagawa T, et al.: Phase II trial of anti-IL-6 receptor antibody (MRA) for children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2003, 48(Suppl):S429.

    Google Scholar 

  82. Hendrickson M: Efficacy of anakinra in refractory systemic arthritis. Arthritis Rheum 2004, 50(Suppl):S438.

    Google Scholar 

  83. Irigoyen PI, Olson J, Hom C, et al.: Treatment of systemic onset juvenile rheumatoid arthritis with anakinra. Arthritis Rheum 2004; 50(Suppl):S437.

    Google Scholar 

  84. Irigoyen PI, Reiff A, Hom C, et al.: Treatment of systemic onset juvenile idiopathic arthritis with anakinra. J Rheum Dis 2005, Submitted. Important study investigating the effect of Il1-Ra in systemic JA.

  85. Lovell DJ, Bowyer SL, Solinger AM: Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2005, 52:1283–1286.

    Article  PubMed  CAS  Google Scholar 

  86. Dailey NJ, Aksentijevich JJ, Chae R, et al.: Interleukin-1 receptor antagonist in the treatment of neonatal onset multisystem inflammatory disease. Arthritis Rheum 2004, 50(Suppl):S1106. Important study investigating the effect of Il1-Ra in periodic fever syndromes.

    Google Scholar 

  87. Agostini L, Martinon F, Burns K, et al.: NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004, 20:319–325.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology and Rehabilitation, Mailstop 60, Childrens Hospital Los Angeles, 4650 Sunset Boulevard, 90027, Los Angeles, CA, USA

    Andreas Reiff MD

Authors
  1. Andreas Reiff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reiff, A. The use of anakinra in juvenile arthritis. Curr Rheumatol Rep 7, 434–440 (2005). https://doi.org/10.1007/s11926-005-0047-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-005-0047-2

Keywords

Search

Navigation